002727SZSE

2025 Annual Report of Independent Director Long Chao

✨ AI Summary

This report details Independent Director Long Chao's performance in 2025 for Yixintang Pharmaceutical Group Co., Ltd. It covers attendance at board and shareholder meetings, committee work, communication with stakeholders, and oversight of key financial and governance matters, affirming adherence to independent director duties and safeguarding shareholder interests.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

2025 Annual Report of Independent Director Long Chao

In November 2025, I was appointed as an independent director of the Seventh Board of Directors of Yixintang Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company"). I have strictly adhered to the requirements of the "Company Law of the People's Republic of China," the "Supervision Rules for Listed Companies," the "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guide No. 1 - Normative Operation of Main Board Listed Companies," and the "Articles of Association" and the "Independent Director Work System." I have upheld the principles of independence, objectivity, and fairness, faithfully performed my duties as an independent director, and effectively protected the overall interests of the Company and the legitimate rights and interests of all shareholders, especially small and medium shareholders. The following is a report on my performance during my term in 2025:

I. Basic Information of Independent Director

(I) Work Experience, Professional Background, and Concurrent Positions

I, Long Chao, am a Chinese national with no permanent overseas residency. Born in November 1964, I hold a Ph.D. in Economics and am a professor and doctoral supervisor at the Yunnan University of Finance and Economics. I am also a director of the Chinese Finance Annual Conference and the leader of the Yunnan Rural Inclusive Finance Development Research Team of the Yunnan Provincial Philosophy and Social Science Innovation Team. I previously served as the Dean of the School of Finance at Yunnan University of Finance and Economics. Since November 17, 2025, I have served as an independent director, chairman of the Remuneration and Nomination Committee, and member of the Nomination Committee of Yixintang Pharmaceutical Group Co., Ltd. I currently also serve as an independent director for Yunnan Tin New Materials Co., Ltd., Yunnan Songming Rural Commercial Bank Co., Ltd., and Yunnan Dali Rural Commercial Bank Co., Ltd.

(II) Statement on Independence

During my term in 2025, I strictly complied with the relevant regulations on independence stipulated in the "Supervision Rules for Listed Companies." I have not held any positions in the Company other than independent director and member of the Board's special committees. I have continuously self-inspected and confirmed that I do not hold more than 1% of the Company's shares, am not employed by the controlling shareholder or its affiliated enterprises, and have no interest relationships with the Company or its major shareholders, or other relationships that may hinder my independent and objective judgment. My independence has been well maintained during my term in 2025.

II. Overview of Independent Director's Performance in 2025

(I) Attendance at Board and Shareholder Meetings

The Company held 8 board meetings in 2025. During my term, I was required to attend 1 board meeting, and my attendance is as follows:

Number of Board Meetings Required to AttendNumber of Board Meetings Actually AttendedNumber of Board Meetings Attended by ProxyNumber of Board Meetings AbsentVoting Results
1100All in favor

The Company held 5 shareholder meetings in 2025. During my term, I was required to attend 1 shareholder meeting, and my attendance is as follows:

Number of Shareholder Meetings Required to AttendNumber of Shareholder Meetings Actually AttendedNumber of Shareholder Meetings Attended by ProxyNumber of Shareholder Meetings Absent
1100

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.